{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:27:10Z","timestamp":1757701630208},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Janssen India"},{"name":"Johnson & Johnson Pvt. Ltd"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To conduct a subgroup analysis of <jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MORE<\/jats:styled-content> trial Part 1, comparing efficacy and safety of add\u2010on subcutaneous golimumab therapy in rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) patients enrolled from and outside India.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MORE<\/jats:styled-content> was an open\u2010label, multicenter, prospective trial of add\u2010on golimumab in biologic\u2010na\u00efve <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients, having active disease despite being on conventional <jats:styled-content style=\"fixed-case\">DMARD<\/jats:styled-content> regimen(s). Part 1 of the study was chosen as the focus of this subgroup analysis because a substantial number of Indian patients (106) were enrolled compared to no Indian patients in Part 2. The primary efficacy outcome was proportion of patients achieving good to moderate <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28\u2010<jats:styled-content style=\"fixed-case\">ESR<\/jats:styled-content> (Disease Activity Score of 28 joints calculated using erythrocyte sedimentation rate) European League Against Rheumatism (<jats:styled-content style=\"fixed-case\">EULAR<\/jats:styled-content>) response at month 6.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Efficacy evaluable population comprised of 105 and 3175 patients from India and outside India, respectively. Safety analysis included 106 patients enrolled from India and 3251 from outside India. A higher proportion of Indian patients had a high disease activity as measured by <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28 <jats:styled-content style=\"fixed-case\">ESR<\/jats:styled-content> than outside India patients. At month 6, the proportion of Indian and non\u2010Indian patients achieving <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28\u2010<jats:styled-content style=\"fixed-case\">ESR<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> DAS<\/jats:styled-content>28 \u2013 C\u2010reactive protein, simplified disease activity index (<jats:styled-content style=\"fixed-case\">SDAI<\/jats:styled-content>) remission, and EuroQoL Quality\u2010of\u2010Life Questionnaire (<jats:styled-content style=\"fixed-case\">EQ<\/jats:styled-content>\u20105D) scores were comparable. Incidence of all adverse events was lower in Indian patients. There were no deaths, cases of tuberculosis or malignancy reported in the patients from India at month 6.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The efficacy and safety results with add\u2010on golimumab were consistent between <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients from India and outside India, despite high baseline disease activity in the Indian patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12927","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T08:38:45Z","timestamp":1469522325000},"page":"1083-1092","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from <scp>GO<\/scp>\u2010<scp>MORE<\/scp> study"],"prefix":"10.1111","volume":"19","author":[{"given":"Sarvajeet","family":"Pal","sequence":"first","affiliation":[{"name":"Advance Rheumatology Clinic Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarath Chandra Mouli","family":"Veeravalli","sequence":"additional","affiliation":[{"name":"Krishna Institute of Medical Sciences Secunderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth Kumar","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Rheumatology RALC Campus King George's Medical University Lucknow India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineeta","family":"Shobha","sequence":"additional","affiliation":[{"name":"St. John's Medical College Hospital Bangalore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramakrishna Rao","family":"Uppuluri","sequence":"additional","affiliation":[{"name":"Sri Deepti Rheumatology Centre Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B G","family":"Dharmanand","sequence":"additional","affiliation":[{"name":"Chanre Rheumatology and Immunology Center and Research Bangalore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Nadkar","sequence":"additional","affiliation":[{"name":"Department of Medicine Seth G.S. Medical College &amp; KEM Hospital Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hsia","sequence":"additional","affiliation":[{"name":"Janssen Global R&amp;D J&amp;J Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyin","family":"Fei","sequence":"additional","affiliation":[{"name":"Janssen Global R&amp;D J&amp;J Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruji","family":"Yao","sequence":"additional","affiliation":[{"name":"Biostatistics Merck Rahway NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Khalifa","sequence":"additional","affiliation":[{"name":"MSD Medical Affairs Luzern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.05.007"},{"key":"e_1_2_8_3_1","first-page":"S14","article-title":"Biologic agents in rheumatoid arthritis: an update for managed care professionals","volume":"17","author":"Agarwal SK","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.12304"},{"key":"e_1_2_8_6_1","unstructured":"Center for Drug Evaluation and Research. Application Number: 125289. Division Director Summary Review. April 2009:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125289s000_SumR.pdf. Accessed on 21 January 2015."},{"key":"e_1_2_8_7_1","first-page":"159","article-title":"Golimumab. A novel human anti\u2010TNF\u2010alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis","volume":"15","author":"Kay J","year":"2010","journal-title":"Core Evid"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq031"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30263"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203229"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111195"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.200317"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756\u2010185X.12723"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"e_1_2_8_16_1","first-page":"144","article-title":"Efficacy and safety of golimumab as add\u2010on therapy to disease\u2010modifying antirheumatic drugs in rheumatoid arthritis: results of the GO\u2010MORE study in Spain","volume":"11","author":"Alonso A","year":"2015","journal-title":"Rheumatol Clin"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23383"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201411"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"},{"issue":"1","key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"i93","DOI":"10.1093\/rheumatology\/keu101.018","article-title":"Final 5\u2010year safety and efficacy results of a phase 3, randomized, placebo\u2010controlled trial of golimumab in methotrexate\u2010na\u00efve patients with Rheumatoid Arthritis","volume":"53","author":"Emery P","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"i99","DOI":"10.1093\/rheumatology\/keu101.031","article-title":"Final 5\u2010year safety and efficacy results of a phase 3, randomized placebo\u2010controlled trial of golimumab in patients with active Rheumatoid Arthritis despite prior treatment with methotrexate","volume":"53","author":"Keystone E","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"i87","DOI":"10.1093\/rheumatology\/keu101.006","article-title":"Final 5\u2010year safety and efficacy results of a phase 3, randomized, placebo\u2010controlled trial of golimumab in patients with active Rheumatoid Arthritis despite previous anti\u2010tumor necrosis factor therapy","volume":"53","author":"Smolen JS","year":"2014","journal-title":"Rheumatology"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009355162"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-013-0010-z"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12927","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12927","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T14:33:30Z","timestamp":1696516410000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/1756-185X.12927"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12927","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]},"assertion":[{"value":"2016-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}